The TRIUMPH Clinical Trial Program: Complete Overview

The TRIUMPH clinical trial program represents Eli Lilly's multi-billion-dollar bet on retatrutide. Launched after Phase 2 results showed unprecedented 24.2% average weight loss (Jastreboff et al., NEJM 2023), TRIUMPH encompasses multiple large-scale Phase 3 trials designed to generate the data needed for FDA approval across several indications. From obesity to diabetes to fatty liver disease, TRIUMPH is testing whether retatrutide can become the most versatile weight loss medication ever approved.

Program Overview

The TRIUMPH program is structured to support retatrutide approval across multiple conditions simultaneously. This approach allows Eli Lilly to pursue multiple FDA indications at once, maximizing the drug's potential reach:

TRIUMPH-1: The Primary Obesity Trial

TRIUMPH-1 is the cornerstone trial. It studies retatrutide in adults with obesity (BMI 30+) or overweight (BMI 27+) with comorbidities, without type 2 diabetes. This is the trial most directly comparable to the Phase 2 data that showed 24.2% weight loss.

Key design features include a longer treatment duration than Phase 2 (72+ weeks vs 48 weeks), multiple dose groups to identify the optimal dose, and a larger sample size to detect less common side effects.

TRIUMPH-2: Obesity with Comorbidities

TRIUMPH-2 specifically enrolls patients who have obesity along with weight-related health conditions such as hypertension, dyslipidemia, or cardiovascular disease risk factors. This trial measures not just weight loss but improvement in these comorbid conditions.

TRIUMPH-3: Type 2 Diabetes

TRIUMPH-3 focuses on patients with type 2 diabetes and obesity, measuring both A1C reduction and weight loss. Phase 2 data in diabetic patients showed A1C reductions of up to 2.02%, making this one of the most anticipated trials.

TRIUMPH-4: Osteoarthritis

TRIUMPH-4 studies whether retatrutide-induced weight loss improves knee osteoarthritis symptoms. Since every pound lost removes approximately 4 pounds of pressure from the knees, the degree of weight loss retatrutide produces could transform osteoarthritis treatment.

TRIUMPH-5: Sleep Apnea

TRIUMPH-5 examines retatrutide's effect on obstructive sleep apnea, measuring changes in the apnea-hypopnea index (AHI). Weight loss of 10-15% often significantly improves sleep apnea; retatrutide's 24%+ loss could potentially resolve it for many patients.

Additional TRIUMPH Trials

Maintenance Study

The maintenance trial addresses a critical question: what happens when patients stop or reduce retatrutide? This trial will inform long-term treatment strategies and help understand whether weight regain can be prevented.

Cardiovascular Outcomes Trial (CVOT)

The cardiovascular outcomes trial is the largest in the program, enrolling approximately 10,000 patients to determine if retatrutide reduces major adverse cardiovascular events (MACE). This trial is critical for demonstrating that weight loss translates to hard cardiovascular outcomes.

MASH/Liver Trial

Given retatrutide's remarkable liver fat reduction (up to 86% in Phase 2), Eli Lilly is also running the SYNERGY-Outcomes trial to establish retatrutide as a treatment for metabolic-associated steatohepatitis (MASH).

Why TRIUMPH Matters for Patients

The breadth of the TRIUMPH program has important implications:

• Multiple indications: If trials succeed across indications, retatrutide could be approved for obesity, diabetes, MASH, and potentially more — making it the most versatile metabolic drug available
• Robust safety data: Thousands of participants across multiple trials will provide comprehensive safety information
• Insurance coverage: Multiple indications increase the likelihood of insurance coverage, as more clinical evidence supports medical necessity
• Clinical confidence: Physicians will have extensive data to guide prescribing decisions for diverse patient populations

Available Now While TRIUMPH Continues

While the TRIUMPH program generates Phase 3 data, proven GLP-1 medications are available today through TRIMI:

• Compounded semaglutide: $99/month
• Compounded tirzepatide: $125/month

Start treatment now and transition to retatrutide when it becomes available. Learn how TRIMI works.